Rilonacept in cryopyrin-associated periodic syndromes: the beginning of longer-acting interleukin-1 antagonism

Affiliations

Comment

Leigh D Church et al. Nat Clin Pract Rheumatol. 2009 Jan.

. 2009 Jan;5(1):14-5.

doi: 10.1038/ncprheum0959. Epub 2008 Nov 18.

¹ Department of Rheumatology, Division of Immunity, Infection and Inflammation, Institute for Biomedical Research, University of Birmingham, Birmingham, UK.

No abstract available

Comment on

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.
Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, Weinstein SP, Belomestnov P, Yancopoulos GD, Stahl N, Mellis SJ. Hoffman HM, et al. Arthritis Rheum. 2008 Aug;58(8):2443-52. doi: 10.1002/art.23687. Arthritis Rheum. 2008. PMID: 18668535 Clinical Trial.
A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.
Goldbach-Mansky R, Shroff SD, Wilson M, Snyder C, Plehn S, Barham B, Pham TH, Pucino F, Wesley RA, Papadopoulos JH, Weinstein SP, Mellis SJ, Kastner DL. Goldbach-Mansky R, et al. Arthritis Rheum. 2008 Aug;58(8):2432-42. doi: 10.1002/art.23620. Arthritis Rheum. 2008. PMID: 18668591 Free PMC article. Clinical Trial.